FDA Determines Regulatory Review Period for ELVITEGRAVIR Patent Extension

Summary

The U.S. Food and Drug Administration (FDA) has officially approved the regulatory review period for ELVITEGRAVIR, a key component of the medication STRIBILD, in order to extend the patent protection for this human drug product.